Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eledon Pharmaceuticals (ELDN) Depreciation and Depletion (2013 - 2017)

Eledon Pharmaceuticals posted quarterly Depreciation and Depletion of $17000.0 for Q1 2017, down 67.92% year-on-year from $53000.0 in Q1 2016, and little changed on a QoQ basis from $17000.0 in Q4 2016.

Eledon Pharmaceuticals (ELDN) has 5 years of Depreciation and Depletion data on file, last reported at $17000.0 in Q1 2017.

  • For the quarter ending Q1 2017, Depreciation and Depletion fell 67.92% year-over-year to $17000.0; the trailing twelve-month figure through Mar 2017 stood at $135000.0 (down 14.01% YoY), and the FY2016 full-year result was $171000.0, up 56.88% from the prior year.
  • Depreciation and Depletion for Q1 2017 stood at $17000.0, roughly flat from $17000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $56000.0 in Q4 2015 and bottomed at $3000.0 in Q4 2013.
  • The 5-year median for Depreciation and Depletion is $16500.0 (2015), against an average of $22928.6.
  • The widest annual swing landed in 2015, when Depreciation and Depletion soared 1020.0%; it then tumbled 69.64% in 2016.
  • A 5-year view of Depreciation and Depletion shows it stood at $3000.0 in 2013, then jumped by 66.67% to $5000.0 in 2014, then jumped by 1020.0% to $56000.0 in 2015, then sank by 69.64% to $17000.0 in 2016, then changed by 0.0% to $17000.0 in 2017.
  • The last three Depreciation and Depletion figures came in at $17000.0 (Q1 2017), $17000.0 (Q4 2016), and $49000.0 (Q3 2016), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation and Depletion (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 1,395.22
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Eledon Pharmaceuticals 419.90 Mn 203.87 Mn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2017 17,000.00
Mar 31, 2017 17,000.00
Dec 31, 2016 17,000.00
Dec 31, 2016 17,000.00
Sep 30, 2016 49,000.00
Sep 30, 2016 49,000.00
Jun 30, 2016 52,000.00
Jun 30, 2016 52,000.00
Mar 31, 2016 53,000.00
Mar 31, 2016 53,000.00
Dec 31, 2015 56,000.00
Dec 31, 2015 56,000.00
Sep 30, 2015 32,000.00
Sep 30, 2015 32,000.00
Jun 30, 2015 16,000.00
Jun 30, 2015 16,000.00
Mar 31, 2015 5,000.00
Mar 31, 2015 5,000.00
Dec 31, 2014 5,000.00
Dec 31, 2014 5,000.00
Sep 30, 2014 5,000.00
Sep 30, 2014 5,000.00
Jun 30, 2014 7,000.00
Jun 30, 2014 7,000.00
Mar 31, 2014 4,000.00
Mar 31, 2014 4,000.00
Dec 31, 2013 3,000.00
Dec 31, 2013 3,000.00